Trials / Completed
CompletedNCT02835508
Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants
A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetic Profile of JNJ-56021927 When Administered as the Tablet Formulation in Healthy Male Japanese Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Janssen Pharmaceutical K.K. · Industry
- Sex
- Male
- Age
- 20 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to assess the safety and Pharmacokinetic (PK) profile of JNJ-56021927 and its active metabolite JNJ-56142060 after single-dose administration of 60 milligram (mg), 120 mg, and 240 mg JNJ-56021927 as the tablet formulation in healthy male Japanese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-56021927 60 Milligram | JNJ-56021927 60 mg oral tablet. |
| DRUG | JNJ-56021927 120 Milligram | JNJ-56021927 120 mg as 2 tablets of 60 mg. |
| DRUG | JNJ-56021927 240 Milligram | JNJ-56021927 240 mg as 4 tablets of 60 mg. |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2016-07-18
- Last updated
- 2017-01-11
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02835508. Inclusion in this directory is not an endorsement.